5 key notes on K2M's stock rating — Now "Strong Buy"

Spinal Tech

K2M received a new rating score for stocks from four different Zacks brokers, according to a Mideast Times report.

Here are five things to know:

 

• The stock has a 1 (strong buy) rating from Zacks Investment
• 12-month consensus target prices is $21
• Earnings per share are expected at $0.33 for the quarter
• K2M traded down 2.38 percent on Monday
• Trading volume is at 142,914

 

At the beginning of January, Piper Jaffray began coverage on K2M shares and set an "overweight" rating at $25 price target.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers